

REMARKS

Applicants elect the invention of Group II, claims 29-36, and Compound No. 99 (pg. 48) for Species I, Compound No. 42 (pg. 50) for Species II, Compound No. 53 (pg. 52) for Species III, and *Retroviridae* for Species IV. The election of *Retroviridae* for Species IV obviates the need for election of Subspecies (a), and cancellation of claim 31 obviates the need to elect a Species V. The election is made with traverse.


We respectfully submit that the restriction requirement referring to Group I (claims 23-28), Group II (claims 32-36) and Group III (claims 37-38) is no longer justified after the cancellation of claims 29-31 and the amendments to claims 32, 37, and 38. Claims 32, 37, and 38 have now been amended to depend from claim 23. Accordingly, the glycopeptides encompassed within claim 23 and amended claims 32, 37, and 38 are the same class of chemical compounds and therefore possess the same technical features and are so closely linked that they should be considered as a single general inventive concept (see M.P.E.P. § 1850). In addition, we note that the International Guidelines provide for Unity of Invention for an independent claim for a given product and an independent claim for a use of the product (see M.P.E.P. § 1893.03(d)).

Should the above argument not be found persuasive, we respectfully request the right to re-join the three Groups in the same application after the subject matter of claim 29 has been found allowable.

Enclosed is a petition to extend the period for reply for three months, to and including August 6, 2007, August 4, 2007 being a Saturday. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: August 6, 2007


James D. DeCamp
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

J. Cooper McDonald, Ph.D. Reg. No. 52,011
--